MetaCap

Bioventus (BVS) vs vVARDIS (VVVV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

vVARDIS is the larger company by market cap ($770.9 million vs $676.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BVS-7.32%VVVV-11.82%
+1%-6%-12%
Nov 13, 20261 yearNov 20, 2026
BVS-7.32%VVVV-11.82%
+1%-6%-12%
Nov 9, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BVS versus VVVV key metrics
MetricBVSVVVV
Share price$9.88$14.55
Market cap$676.53M$770.91M
1-day change-0.70%-3.00%
YTD return+32.80%—
1-year return+36.46%—
5-year return-21.02%—
P/E ratio (TTM)12.20—
Forward P/E11.13—
EPS (TTM)$0.81$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$568.09M—
Revenue growth (YoY)-0.91%—
Net income (latest FY)$22.73M—
Gross margin68.33%—
Operating margin9.50%—
Net margin4.00%—
52-week high$15.89$16.95
52-week low$7.02$14.00
Distance from 52-week high-37.83%-14.16%
Analyst consensusnone—
Avg. price target upside+68.02%—
Average volume536.81K963.08K
Shares outstanding68.47M38.59M
Employees960153
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bioventus

BVS stock →

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.

Health Care · Medical/Dental Instruments · 960 employees

About vVARDIS

VVVV stock →

vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel.

Health Care · Medical/Dental Instruments · 153 employees

BVS vs VVVV FAQ

Which is bigger, Bioventus or vVARDIS?

vVARDIS (VVVV) is larger, with a market capitalization of $770.91M compared with $676.53M for Bioventus (BVS).

Are Bioventus and vVARDIS in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons